Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

However, sales of these products started declining as the outbreak receded, leading to more uneven revenue growth for the company. Throughout it all, one of Abbott Laboratories' segments has been ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE: ABT) with an "overweight" rating and a price target of $131 ...

Abbott Laboratories Background Information (This ... with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues ...

"Abbott Laboratories began its 125th year with approximately ... "For our shareholders, we are developing the kind of essential, life-enhancing products that will ensure the enduring growth ...

O'Melveny & Myers is defending Abbott Laboratories in a pending class action against the ... Ohio-based consumer goods ...